We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Apellis Pharmaceuticals announced the company will not pursue additional development of APL-9, an investigational targeted C3 therapy designed for acute interventions, for the treatment of severe COVID-19.
Apellis Pharmaceuticals announced the company has initiated a Phase 1/2 clinical study of APL-9, an investigational C3 inhibitor designed for acute interventions ...